Immunometabolites prolong TB biofilms by enabling respiratory flexibility

Tuberculosis is caused by Mycobacterium tuberculosis and is famous for forming organized structures in the lung called granuloma. Those multicellular arrangements have been studied for decades, but another lifestyle of the bacterium — biofilms, which are communities of cells that cling together and to surfaces — has received less metabolic attention despite its relevance to disease outcomes. In new work led by Amitesh Anand, researchers turned their focus to the chemical environment that surrounds mycobacterial biofilms inside the body. Rather than looking at immune cells or drugs, the team explored how small metabolic molecules produced during infection — called immunometabolites — change what biofilms do and how long they last. The study tested whether providing specific immunometabolites to mycobacterial communities would alter their fate, and the results point to a surprisingly direct connection between the respiratory options available to bacteria and the structural longevity of biofilms in the lung.

The core experimental finding reported is straightforward: supplementation of immunometabolites, nitrate or fumarate, extends mycobacterial biofilm lifespan dramatically. When these alternative electron acceptors were made available, biofilms stayed intact for much longer than they did without supplementation. Molecular analysis showed this longevity was enabled by suppression of dormancy regulons and by maintenance of an active metabolic state rather than entry into dormancy. In other words, access to alternative electron acceptors directly influences mycobacterial biofilm fate. By linking the suppression of dormancy programs to prolonged structural integrity of the community, the work identifies respiratory flexibility — the ability of bacteria to use different electron acceptors like nitrate or fumarate — as a determinant of mycobacterial biofilm persistence.

These findings shift attention from only the immune structures like granuloma to the chemical and metabolic landscape that surrounds bacteria during infection. If immunometabolites such as nitrate and fumarate can keep biofilms metabolically active and structurally intact, then changing the availability of those molecules in the lung could alter how long biofilms persist. The study highlights respiratory flexibility as a central metabolic lever that dictates biofilm survival and suggests new strategies for disrupting mycobacterial biofilms by targeting their respiratory choices or the local chemistry that supplies alternative electron acceptors. Importantly, the authors note these insights open new avenues for targeting mycobacterial biofilms in clinical settings, pointing toward metabolic interventions as a potential complement to traditional antimicrobial approaches.